CN110621303A - 抗TNFα抗体的液体制剂 - Google Patents

抗TNFα抗体的液体制剂 Download PDF

Info

Publication number
CN110621303A
CN110621303A CN201880031705.6A CN201880031705A CN110621303A CN 110621303 A CN110621303 A CN 110621303A CN 201880031705 A CN201880031705 A CN 201880031705A CN 110621303 A CN110621303 A CN 110621303A
Authority
CN
China
Prior art keywords
formulation
liquid formulation
adalimumab
concentration
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880031705.6A
Other languages
English (en)
Chinese (zh)
Inventor
尹素罗
高衍庆
苏震彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
LG Corp
Original Assignee
LG Chem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110621303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LG Chem Ltd filed Critical LG Chem Ltd
Publication of CN110621303A publication Critical patent/CN110621303A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880031705.6A 2017-03-16 2018-03-16 抗TNFα抗体的液体制剂 Pending CN110621303A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0033188 2017-03-16
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
CN110621303A true CN110621303A (zh) 2019-12-27

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031705.6A Pending CN110621303A (zh) 2017-03-16 2018-03-16 抗TNFα抗体的液体制剂

Country Status (15)

Country Link
JP (2) JP7109849B2 (ru)
KR (2) KR20180106974A (ru)
CN (1) CN110621303A (ru)
AU (1) AU2018236651B2 (ru)
BR (1) BR112019019162A2 (ru)
CO (1) CO2019010860A2 (ru)
MA (1) MA46988A1 (ru)
MX (1) MX2019010895A (ru)
MY (1) MY197202A (ru)
NZ (1) NZ757965A (ru)
PH (1) PH12019502075A1 (ru)
RU (1) RU2756619C2 (ru)
UA (1) UA123847C2 (ru)
WO (1) WO2018169348A1 (ru)
ZA (1) ZA201906696B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021164717A1 (zh) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 抗TNF-α的抗体制剂及其制备方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159614A (zh) * 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂
CN104623656A (zh) * 2011-06-03 2015-05-20 株式会社Lg生命科学 依那西普的稳定液体制剂
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
PT2946765T (pt) * 2014-05-23 2016-11-10 Ares Trading Sa Composição farmacêutica líquida
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
UY36542A (es) * 2015-01-28 2016-08-31 Mabxience S A Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623656A (zh) * 2011-06-03 2015-05-20 株式会社Lg生命科学 依那西普的稳定液体制剂
CN104159614A (zh) * 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021164717A1 (zh) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 抗TNF-α的抗体制剂及其制备方法和用途

Also Published As

Publication number Publication date
ZA201906696B (en) 2020-08-26
UA123847C2 (uk) 2021-06-09
JP2020510079A (ja) 2020-04-02
KR102342292B1 (ko) 2021-12-24
RU2756619C2 (ru) 2021-10-04
WO2018169348A1 (ko) 2018-09-20
JP2022097600A (ja) 2022-06-30
NZ757965A (en) 2022-07-01
PH12019502075A1 (en) 2020-09-14
AU2018236651B2 (en) 2020-12-10
JP7109849B2 (ja) 2022-08-01
RU2019130728A3 (ru) 2021-04-16
CO2019010860A2 (es) 2020-01-17
RU2019130728A (ru) 2021-04-16
MX2019010895A (es) 2019-11-05
MY197202A (en) 2023-05-31
KR20180106974A (ko) 2018-10-01
BR112019019162A2 (pt) 2020-04-14
KR20200096472A (ko) 2020-08-12
MA46988A1 (fr) 2020-06-30
AU2018236651A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US20190345238A1 (en) Formulations
AU2007307107B2 (en) Stable antibody formulations
AU2007240732B2 (en) Buffering agents for biopharmaceutical formulations
WO2016128564A1 (en) Stable liquid formulation for monoclonal antibodies
KR102342292B1 (ko) 항-tnf 알파 항체의 액상 제제
AU2013255413A1 (en) Pharmaceutical formulations of TNF-alpha antibodies
EP2863951A1 (en) Pharmaceutical formulation for a therapeutic antibody
EP4119161A1 (en) Liquid pharmaceutical composition having improved stability
EP4186492A1 (en) Ophthalmic liquid composition
EP3909607A1 (en) Pharmaceutical composition comprising antibody, device comprising same, and use thereof
TWI771335B (zh) 穩定藥學調配物
AU2014201388C1 (en) Stable Buffered Formulations Containing Polypeptides
CN118056572A (zh) 含有抗il-17抗体的稳定制剂
AU2016213875A1 (en) Stable Buffered Formulations Containing Polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination